



UNITED STATES PATENT AND TRADEMARK OFFICE

1

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/498,046	02/04/2000	Sabine Neirynek	VIB-08	8244
<div>7590 James F. Haley Jr. Fish & Neave 1251 Avenue of the Americas New York, NY 10020-1104</div>			<div>EXAMINER CHEN, STACY BROWN</div>	
			<div>ART UNIT 1648</div>	<div>PAPER NUMBER</div>
SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE		
3 MONTHS	01/10/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

09/498,046

Applicant(s)

NEIRYNCK ET AL.

Examiner

Stacy B. Chen

Art Unit

1648

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 October 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 26-32, 34 and 36-57 is/are pending in the application.
- 4a) Of the above claim(s) 42-45 and 47-51 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 26, 27, 36-38, 40, 41, 46 and 54-57 is/are rejected.
- 7) ☒ Claim(s) 28-32, 34, 39, 52 and 53 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 19, 2006 has been entered.

The rejection of claims 26-32, 34, 36-41, 46 and 52-57 under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement is withdrawn in view of Applicant's amendment.

Claims Summary

The claims are drawn to an immunogenic composition comprising a fusion product. The fusion product is comprised of one of the following constructs:

- An immunogenic extracellular part of an M2 membrane protein of a human influenza A virus and a heterologous presenting carrier.
- An immunogenic extracellular part of an NB protein of a human influenza B virus and a heterologous presenting carrier.
- An immunogenic extracellular part of a CM2 protein of a human influenza C virus and a heterologous presenting carrier.

The presenting carrier is a peptide or polypeptide. Specifically, the peptide or polypeptide is a hepatitis B core protein, C3d, polypeptides comprising multiple copies of C3d, tetanus toxin fragment C or yeast Ty particles. In another embodiment, the carrier is a non-peptidic structure.

Art Unit: 1648

The fusion product is in an isolated form. The fusion product may also be anchored in the membrane of an acceptor cell expressing the fusion product. The fusion product is part of a lipid bilayer or cell wall. The amino acid sequence of the entire extracellular domain is SEQ ID NO: 1, 2 or 3.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

(New Rejection) Claims 34, 39, 52 and 53 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims recite the limitations, "the vaccine", or, "the influenza vaccine". There is insufficient antecedent basis for these limitations in the claims.

Claim Rejections - 35 USC § 102

(New Rejection) Claims 26, 27, 36, 37, 38, 40, 41, 46 and 54-56 are rejected under 35 U.S.C. 102(b) as being anticipated by Kurtz *et al.* (U.S. Patent 5,691,189, "Kurtz"). The claims are summarized above. Kurtz discloses the expression of influenza A virus M2 protein from *S. cerevisiae* cells (abstract). *S. cerevisiae* cells are a heterologous presenting carrier. The M2 protein is expected to be fused to the cells since the M2 gene is engineered to be expressed by the cells (col. 3, lines 25-31). The M2 protein is a protein having at least the smallest portion of the full-length wild-type M2 protein that results in growth impairment in *S. cerevisiae* cells (col.

Art Unit: 1648

3, lines 32-36). Kurtz's M2 protein is expected to contain an immunogenic extracellular part of the M2 because the protein is disclosed to associate into tetramers to form ion channels (col. 1, lines 37-42). Since Kurtz teaches that one of the uses for the M2 protein expressed on yeast cells is in an assay to detect modulators of the M2 ion channel, the extracellular part of M2 must be expressed in Kurtz's construct. Kurtz discloses that the inhibitors of the M2 channel would be effective antiviral agents (col. 1, lines 51-52).

Kurtz does not mention whether the influenza A is human. Kurtz's SEQ ID NO: 3 contains Applicant's SEQ ID NO: 1, which is human. Since the sequences are identical, Kurtz's composition must be comprised of an immunogenic extracellular part of an M2 of a human influenza A virus.

Although Kurtz does not disclose the yeast cell/M2 constructs as compositions to be administered to humans or other animal species, the claims are drawn to products. The intended uses of the products are not given patentable weight. The structural limitations of the claims have been met by the teachings of Kurtz.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

(*New Rejection*) Claims 26, 27, 36, 37, 38, 40, 41, 46 and 54-57 are rejected under 35 U.S.C. 103(a) as being unpatentable over Kurtz in view of Sunstrom *et al.* (*J. Membrane Biol.*

Art Unit: 1648

1996, 150:127-132, "Sunstrom"). The claims and the teachings of Kurtz are summarized above. Although Kurtz does not disclose the use of the human influenza B virus NB protein, Sunstrom discloses that influenza B virus NB protein forms ion channels (abstract). (Influenza B viruses are known to infect humans only, thus the NB protein from influenza B must be a human protein.) It would have been obvious to substitute the NB protein of Sunstrom into Kurtz's *S. cerevisiae* cells. Kurtz teaches that one of the uses for the M2 protein expressed on yeast cells is in an assay to detect modulators of the M2 ion channel, thus identifying inhibitors of the M2 channel as effective antiviral agents (Kurtz, col. 1, lines 51-52). One would have been motivated to substitute the ion channel forming protein NB of influenza B virus for the M2 channel in order to identify inhibitors of the influenza B ion channel, NB. One would have had a reasonable expectation of success that the ion channel of the influenza B virus would have been successfully expressed from Kurtz's *S. cerevisiae* cells because the ion channel protein of influenza A virus (M2) was successfully expressed from *S. cerevisiae* cells. Therefore, the embodiment of the influenza B virus NB protein would have been obvious to one of ordinary skill in the art at the time the instant invention was made.

Conclusion

Claims 28-32, 34, 39, 52 and 53 are objected to for depending from rejected claims.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR

Art Unit: 1648

system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stacy B. Chen whose telephone number is 571-272-0896. The examiner can normally be reached on M-F (7:00-4:30). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Stacy B. Chen 1/8/07
STACY B. CHEN
PRIMARY EXAMINER